Last $275.07 USD
Change Today +2.72 / 1.00%
Volume 121.5K
PBYI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

puma biotechnology inc (PBYI) Snapshot

Open
$274.10
Previous Close
$272.35
Day High
$276.00
Day Low
$271.27
52 Week High
08/26/14 - $279.37
52 Week Low
11/12/13 - $33.70
Market Cap
8.3B
Average Volume 10 Days
200.2K
EPS TTM
$-3.02
Shares Outstanding
30.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PUMA BIOTECHNOLOGY INC (PBYI)

puma biotechnology inc (PBYI) Related Businessweek News

No Related Businessweek News Found

puma biotechnology inc (PBYI) Details

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products to enhance cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

97 Employees
Last Reported Date: 08/11/14
Founded in 2010

puma biotechnology inc (PBYI) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: $806.7K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $366.4K
Senior Vice President of Clinical Research an...
Total Annual Compensation: $433.0K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $375.2K
Compensation as of Fiscal Year 2013.

puma biotechnology inc (PBYI) Key Developments

Puma Biotechnology, Inc. Announces Board Changes

On August 27, 2014, Dr. Richard B. Phillips, Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance, notified Puma Biotechnology, Inc. that he will be retiring for health reasons effective during the fourth quarter of 2014 (and no later than November 7, 2014). Effective upon Dr. Phillips' departure, his regulatory responsibilities will be assumed by Erin Jones, the company's current Vice President, Global Regulatory Affairs. Prior to joining Puma, Mr. Jones worked at Genentech, where he held a variety of positions including North America Oncology Team Leader.

Puma Biotechnology, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014

Puma Biotechnology, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.

Puma Biotechnology, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Puma Biotechnology, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $38.9 million against $12.7 million a year ago. Net loss was $38.8 million or $1.29 basic and diluted per share against $12.6 million or $0.44 basic and diluted per share a year ago. Non-GAAP loss from operations was $31.7 million against $11.3 million a year ago. Non-GAAP net loss applicable to common stock was $31.7 million $1.05 diluted per share against $11.3 million or $0.39 diluted per share a year ago. Net cash used in operating activities for the second quarter of 2014 was $17.4 million. For the six months, the company reported loss from operations of $58.7 million against $24.5 million a year ago. Net loss was $58.6 million or $1.96 basic and diluted per share against $24.4 million or $0.85 basic and diluted per share a year ago. Cash provided used in operating activities was $34.4 million against $29.5 million a year ago. Non-GAAP loss from operations was $46.4 million against $21.9 million a year ago. Non-GAAP net loss applicable to common stock was $46.3 million $1.55 diluted per share against $21.9 million or $0.76 diluted per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBYI:US $275.07 USD +2.72

PBYI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBYI.
View Industry Companies
 

Industry Analysis

PBYI

Industry Average

Valuation PBYI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 49.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PUMA BIOTECHNOLOGY INC, please visit www.pumabiotechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.